Effects of 4-Hydroxyandrostenedione and Goserelin in Breast Cancer
Author Information
Author(s): R.C. Stein, M. Dowsett, A. Hedley, J.-C. Gazet, H.T. Ford, R.C. Coombes
Primary Institution: St George's Hospital Medical School
Hypothesis
Can 4-hydroxyandrostenedione (40HA) effectively treat premenopausal women with advanced breast cancer when used alone or in combination with goserelin?
Conclusion
The combination of 4-hydroxyandrostenedione and goserelin leads to significant suppression of oestradiol levels, but 40HA alone is not effective in treating premenopausal breast cancer.
Supporting Evidence
- 40HA alone did not significantly reduce serum oestradiol levels in premenopausal women.
- Three out of four patients treated with goserelin after 40HA showed objective responses.
- Combined treatment with goserelin and 40HA led to further suppression of oestradiol levels.
Takeaway
This study looked at how two drugs, 40HA and goserelin, work together to help women with breast cancer. They found that using both together can lower a hormone that helps the cancer grow.
Methodology
Twelve premenopausal women with metastatic breast cancer were treated with 40HA and goserelin, with hormone levels measured before and during treatment.
Limitations
The study had a small sample size and did not find consistent results in hormone suppression with 40HA alone.
Participant Demographics
Median age of participants was 49 years, with a range of 42-52 years.
Statistical Information
P-Value
p<0.001
Statistical Significance
p<0.001
Want to read the original?
Access the complete publication on the publisher's website